Search

Your search keyword '"Fouque D"' showing total 340 results
Start Over Author "Fouque D" Search Limiters Full Text
340 results on '"Fouque D"'

1. Erratum

Author

Slee, A, McKeaveney, C, Adamson, G, Davenport, A, Far-Rington, K, Fouque, D, Kalantar-Zadeh, K, Mallett, J, Maxwell, AP, Mullan, R, Noble, H, O'Donoghue, D, Porter, S, Seres, DS, Shields, J, Witham, M, and Reid, J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Nutrition and Dietetics, Urology & Nephrology, Clinical sciences, Nutrition and dietetics
Published
2021

2. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.

Author

Fouque, D, Kalantar-Zadeh, K, Kopple, J, Cano, N, Chauveau, P, Cuppari, L, Franch, H, Guarnieri, G, Ikizler, TA, Kaysen, G, Lindholm, B, Massy, Z, Mitch, W, Pineda, E, Stenvinkel, P, Treviño-Becerra, A, and Wanner, C

Subjects
Humans, Kidney Diseases, Wasting Syndrome, Malnutrition, Syndrome, Acute Disease, Chronic Disease, Inflammation, Cachexia, Proteins, Energy Metabolism, Terminology as Topic, malnutrition, inflammation, protein-energy wasting, cachexia, kidney disease wasting, anorexia, Urology & Nephrology, Clinical Sciences
Abstract

The recent research findings concerning syndromes of muscle wasting, malnutrition, and inflammation in individuals with chronic kidney disease (CKD) or acute kidney injury (AKI) have led to a need for new terminology. To address this need, the International Society of Renal Nutrition and Metabolism (ISRNM) convened an expert panel to review and develop standard terminologies and definitions related to wasting, cachexia, malnutrition, and inflammation in CKD and AKI. The ISRNM expert panel recommends the term 'protein-energy wasting' for loss of body protein mass and fuel reserves. 'Kidney disease wasting' refers to the occurrence of protein-energy wasting in CKD or AKI regardless of the cause. Cachexia is a severe form of protein-energy wasting that occurs infrequently in kidney disease. Protein-energy wasting is diagnosed if three characteristics are present (low serum levels of albumin, transthyretin, or cholesterol), reduced body mass (low or reduced body or fat mass or weight loss with reduced intake of protein and energy), and reduced muscle mass (muscle wasting or sarcopenia, reduced mid-arm muscle circumference). The kidney disease wasting is divided into two main categories of CKD- and AKI-associated protein-energy wasting. Measures of chronic inflammation or other developing tests can be useful clues for the existence of protein-energy wasting but do not define protein-energy wasting. Clinical staging and potential treatment strategies for protein-energy wasting are to be developed in the future.

Published
2008

4. Brain dysfunction in tubular and tubulointerstitial kidney diseases

Author

Viggiano D, Bruchfeld A, Carriazo S, de Donato A, Endlich N, Ferreira AC, Figurek A, Fouque D, Franssen CFM, Giannakou K, Goumenos D, Hoorn EJ, Nitsch D, Arduan AO, Pešić V, Rastenyté D, Soler MJ, Rroji M, Trepiccione F, Unwin RJ, Wagner CA, Wiecek A, Zacchia M, Zoccali C, Capasso G, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)., Viggiano, D, Bruchfeld, A, Carriazo, S, de Donato, A, Endlich, N, Ferreira, Ac, Figurek, A, Fouque, D, Franssen, Cfm, Giannakou, K, Goumenos, D, Hoorn, Ej, Nitsch, D, Arduan, Ao, Pešić, V, Rastenyté, D, Soler, Mj, Rroji, M, Trepiccione, F, Unwin, Rj, Wagner, Ca, Wiecek, A, Zacchia, M, Zoccali, C, Capasso, G, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative, Target)., NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), CarMeN, laboratoire, University of the Study of Campania Luigi Vanvitelli, Karolinska University Hospital [Stockholm], Linköping University (LIU), IIS‑Fundación Jiménez Diaz‑Autonoma University [Madrid, Spain], University of Medicine Greifswald, Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Universität Zürich [Zürich] = University of Zurich (UZH), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), University of Groningen [Groningen], European University of Cyprus, General University Hospital of Patras, Erasmus University Medical Center [Rotterdam] (Erasmus MC), London School of Hygiene and Tropical Medicine (LSHTM), University of Belgrade [Belgrade], Lithuanian University of health Sciences [Kaunas], Vall d’Hebron Research Institute (VHIR), University Hospital Center 'Mother Tereza' [Tirana, Albania] (UHCMT), University College of London [London] (UCL), Medical University of Silesia (SUM), Renal Research Institute [New York, NY, USA] (2RI), CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target): Giovambattista Capasso, Alexandre Andrade, Maie Bachmann, Inga Bumblyte, Adrian Constantin Covic, Pilar Delgado, Nicole Endlich, Andreas Engvig, Denis Fouque, Casper Franssen, Sebastian Frische, Liliana Garneata, Loreto Gesualdo, Konstantinos Giannakou, Dimitrios Goumenos, Ayşe Tuğba Kartal, Laila-Yasmin Mani, Hans-Peter Marti, Christopher Mayer, Rikke Nielsen, Vesna Pšić, Merita Rroji Molla, Giorgos Sakkas, Goce Spasovski, Kate I Stevens, Evgueniy Vazelov, Davide Viggiano, Lefteris Zacharia, Ana Carina Ferreira, Jolanta Malyszko, Ewout Hoorn, Andreja Figurek, Robert Unwin, Carsten A Wagner, Christoph Wanner, Annette Bruchfeld, Marion Pépin, Andrzej Wieçek, Dorothea Nitsch, Ivo Fridolin, Gaye Hafez, Maria José Soler, Michelangela Barbieri, Bojan Batinić, Laura Carrasco, Sol Carriazo, Ron Gansevoort, Gianvito Martino, Francesco Mattace Raso, Ionut Nistor, Alberto Ortiz, Giuseppe Paolisso, Daiva Rastenytė, Gabriel Stefan, Gioacchino Tedeschi, Ziad A Massy, Boris Bikbov, Karl Hans Endlich, Olivier Godefroy, Jean-Marc Chillon, Anastassia Kossioni, Justina Kurganaite, Norberto Perico, Giuseppe Remuzzi, Tomasz Grodzicki, Francesco Trepiccione, Carmine Zoccali, Mustafa Arici, Peter Blankestijn, Kai-Uwe Eckardt, Danilo Fliser, Eugenio Gutiérrez Jiménez, Maximilian König, Ivan Rychlik, Michela Deleidi, George Reusz, and Internal Medicine

Subjects
ACIDOSIS, [SDV]Life Sciences [q-bio], Review, Disease, electrolyte, 030204 cardiovascular system & hematology, urologic and male genital diseases, 0302 clinical medicine, Child, 610 Medicine & health, MUTATION, 0303 health sciences, Kidney, Proteinuria, Reabsorption, female genital diseases and pregnancy complications, 3. Good health, [SDV] Life Sciences [q-bio], BARTTER-SYNDROME, medicine.anatomical_structure, Nephrology, Child, Preschool, GITELMANS-SYNDROME, Kidney Diseases, medicine.symptom, Glomerular Filtration Rate, medicine.medical_specialty, brain, chronic kidney disease, cognitive function, tubulointerstitial, Urology, Renal function, 03 medical and health sciences, SDG 3 - Good Health and Well-being, medicine, Humans, Renal Insufficiency, Chronic, AcademicSubjects/MED00340, NEPHRITIS, 030304 developmental biology, Rheumatology and Autoimmunity, Transplantation, Reumatologi och inflammation, HYPONATREMIA, business.industry, urogenital system, AQP2, medicine.disease, Nephrogenic diabetes insipidus, GENE, KLOTHO, MODEL, Nephritis, Interstitial, business, Tubulointerstitial Disease, Kidney disease
Abstract

Funding: This article is published as part of a supplement financially supported by the COST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT). Kidney function has two important elements: glomerular filtration and tubular function (secretion and reabsorption). A persistent decrease in glomerular filtration rate (GFR), with or without proteinuria, is diagnostic of chronic kidney disease (CKD). While glomerular injury or disease is a major cause of CKD and usually associated with proteinuria, predominant tubular injury, with or without tubulointerstitial disease, is typically non-proteinuric. CKD has been linked with cognitive impairment, but it is unclear how much this depends on a decreased GFR, altered tubular function or the presence of proteinuria. Since CKD is often accompanied by tubular and interstitial dysfunction, we explore here for the first time the potential role of the tubular and tubulointerstitial compartments in cognitive dysfunction. To help address this issue we selected a group of primary tubular diseases with preserved GFR in which to review the evidence for any association with brain dysfunction. Cognition, mood, neurosensory and motor disturbances are not well characterized in tubular diseases, possibly because they are subclinical and less prominent than other clinical manifestations. The available literature suggests that brain dysfunction in tubular and tubulointerstitial diseases is usually mild and is more often seen in disorders of water handling. Brain dysfunction may occur when severe electrolyte and water disorders in young children persist over a long period of time before the diagnosis is made. We have chosen Bartter and Gitelman syndromes and nephrogenic diabetes insipidus as examples to highlight this topic. We discuss current published findings, some unanswered questions and propose topics for future research. publishersversion published

Published
2022
Full Text
View/download PDF

6. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

Author

Goldsmith, David, Covic, Adrian, Vervloet, Marc, Cozzolino, Mario, Nistor, Ionut, Cozzolino, Mario, Vervloet, Mark, Brandenburg, Vincent, Bover, Jordi, Covic, Adrian, Evenepoel, Pieter, Goldsmith, David, Massy, Ziad, Mazzaferro, Sandro, Urena-Torres, Pablo, Abramowicz, D., Bolignano, D., Cannata Andia, G., Cochat, P., Covic, A., Delvecchio, L., Drechsler, C., Eckardt, K.U., Fouque, D., Fox, J., Haller, M., Heimburger, O., Jager, K.J., Lindley, E., Marti Monros, A.M., Nagler, E., Oberbauer, R., Spasovski, G., Tattersall, J., Van Biesen, W., vander Veer, S., Vanholder, R., Wanner, C., Wheeler, D., Whithers, W., Wiecek, A., and Zoccali, C.

Published
2015
Full Text
View/download PDF

7. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Author

Ortiz, A, Cozzolino, M, Duivenvoorden, R, Fliser, D, Fouque, D, Franssen, CFM, Goumenos, D, Hemmelder, MH, Hilbrands, LB, Jager, KJ, Massy, ZA, Noordzij, M, Rosenkranz, AR, Rychlik, I, Soler, MJ, Stevens, K, Torra, R, Tuglular, S, Vart, P, Wanner, C, Gansevoort, RT, ERA-EDTA Council, and Eracoda Working Grp

Subjects
risk factor, prevalence, COVID-19, mortality, renal replacement therapy, chronic kidney disease
Abstract

Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR

Published
2021

8. Erratum to: Using a generic definition of cachexia to understand clinical characteristics and mortality in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study

Author

Mckeaveney, C., Slee, A., Adamson, G., Davenport, A., Farrington, K., Fouque, D., Kalanter-Zadeh, K., Mallett, J., Maxwell, A. P., Mullan, R., Noble, H., O'Donoghue, D., Porter, S., Seres, D. S., Shields, J., Witham, M., Reid, J., University College of London [London] (UCL), University of Ulster, School of Metallurgy and Materials, University of Birmingham [Birmingham], University of Hertfordshire [Hatfield] (UH), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University of California [Irvine] (UCI), University of California, Royal Victoria Hospital [Belfast, UK], Queen's University [Belfast] (QUB), Belfast City Hospital, Antrim Area Hospital - Northern Health and Social Care Trust [Antrim, Northern Ireland] (AAH-NHSCT), University of Manchester [Manchester], Bournemouth University [Poole] (BU), New York Presbyterian Hospital, Newcastle University [Newcastle], University of California [Irvine] (UC Irvine), University of California (UC), and CarMeN, laboratoire

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021
Full Text
View/download PDF

9. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Author

Ortiz, A., Cozzolino, M., Duivenvoorden, R., Fliser, D., Fouque, D., Franssen, C.F., Goumenos, D., Hemmelder, M.H., Hilbrands, L.B., Jager, K.J., Massy, Z.A., Noordzij, Marlies, Rosenkranz, A., Rychlık, I., Soler, M.J., Stevens, K., Torra, R., Tuglular, S., Vart, P., Wanner, C., Gansevoort, R.T., Ortiz, A., Cozzolino, M., Duivenvoorden, R., Fliser, D., Fouque, D., Franssen, C.F., Goumenos, D., Hemmelder, M.H., Hilbrands, L.B., Jager, K.J., Massy, Z.A., Noordzij, Marlies, Rosenkranz, A., Rychlık, I., Soler, M.J., Stevens, K., Torra, R., Tuglular, S., Vart, P., Wanner, C., and Gansevoort, R.T.

Abstract

Contains fulltext : 232029.pdf (Publisher’s version ) (Open Access)

Published
2021

10. Plant-based diets to manage the risks and complications of chronic kidney disease

Author

Carrero JJ, González-Ortiz A, Avesani CM, Bakker SJL, Bellizzi V, Chauveau P, Clase CM, Cupisti A, Espinosa-Cuevas A, Molina P, Moreau K, Piccoli GB, Post A, Sezer S, and Fouque D

Subjects
food and beverages
Abstract

Traditional dietary recommendations for patients with chronic kidney disease (CKD) focus on the quantity of nutrients consumed. Without appropriate dietary counselling, these restrictions can result in a low intake of fruits and vegetables and a lack of diversity in the diet. Plant nutrients and plant-based diets could have beneficial effects in patients with CKD: increased fibre intake shifts the gut microbiota towards reduced production of uraemic toxins; plant fats, particularly olive oil, have anti-atherogenic effects; plant anions might mitigate metabolic acidosis and slow CKD progression; and as plant phosphorus has a lower bioavailability than animal phosphorus, plant-based diets might enable better control of hyperphosphataemia. Current evidence suggests that promoting the adoption of plant-based diets has few risks but potential benefits for the primary prevention of CKD, as well as for delaying progression in patients with CKD G3-5. These diets might also help to manage and prevent some of the symptoms and metabolic complications of CKD. We suggest that restriction of plant foods as a strategy to prevent hyperkalaemia or undernutrition should be individualized to avoid depriving patients with CKD of these potential beneficial effects of plant-based diets. However, research is needed to address knowledge gaps, particularly regarding the relevance and extent of diet-induced hyperkalaemia in patients undergoing dialysis. Emerging evidence suggests that plant-based diets could help to prevent chronic kidney disease (CKD), manage its symptoms and metabolic complications and delay disease progression. Here, the authors discuss the potential risks and benefits of these diets in patients with CKD, as well as implementation strategies and knowledge gaps.

Published
2020

11. Mild cognitive impairment and kidney disease: clinical aspects

Author

Viggiano, D. (Davide), Wagner, C.A. (Carsten), Blankestijn, P.J. (Peter), Bruchfeld, A. (Annette), Fliser, D. (Danilo), Fouque, D. (Denis), Frische, S. (Sebastian), Gesualdo, L. (Loreto), Gutiérrez, E. (Eugenio), Goumenos, D. (Dimitrios), Hoorn, E.J. (Ewout), Eckardt, K.-U. (Kai-Uwe), Knauß, S. (Samuel), König, M. (Maximilian), Malyszko, J. (Jolanta), Massy, Z. (Ziad), Nitsch, R. (Robert), Pesce, F. (Francesco), Rychlík, I. (Ivan), Soler, M.J. (Maria Jose), Spasovski, G. (Goce), Stevens, K.I. (Kathryn I.), Trepiccione, F. (Francesco), Wanner, C. (Christoph), Wiecek, A. (Andrzej), Zoccali, C. (Carmine), Unwin, R.J. (Robert John), Capasso, G. (Giovambattista), Viggiano, D. (Davide), Wagner, C.A. (Carsten), Blankestijn, P.J. (Peter), Bruchfeld, A. (Annette), Fliser, D. (Danilo), Fouque, D. (Denis), Frische, S. (Sebastian), Gesualdo, L. (Loreto), Gutiérrez, E. (Eugenio), Goumenos, D. (Dimitrios), Hoorn, E.J. (Ewout), Eckardt, K.-U. (Kai-Uwe), Knauß, S. (Samuel), König, M. (Maximilian), Malyszko, J. (Jolanta), Massy, Z. (Ziad), Nitsch, R. (Robert), Pesce, F. (Francesco), Rychlík, I. (Ivan), Soler, M.J. (Maria Jose), Spasovski, G. (Goce), Stevens, K.I. (Kathryn I.), Trepiccione, F. (Francesco), Wanner, C. (Christoph), Wiecek, A. (Andrzej), Zoccali, C. (Carmine), Unwin, R.J. (Robert John), and Capasso, G. (Giovambattista)

Published
2020
Full Text
View/download PDF

12. Mild cognitive impairment and kidney disease: clinical aspects

Author

Viggiano, D, Wagner, CA, Blankestijn, PJ, Bruchfeld, A, Fliser, D, Fouque, D, Frische, S, Gesualdo, L, Gutierrez, E, Goumenos, D, Hoorn, Ewout, Eckardt, KU, Knauss, S, Konig, M, Malyszko, J, Massy, Z, Nitsch, D, Pesce, F, Rychlik, I, Soler, MJ, Spasovski, G, Stevens, KI, Trepiccione, F, Wanner, C, Wiecek, A, Zoccali, C, Unwin, R, Capasso, G, Viggiano, D, Wagner, CA, Blankestijn, PJ, Bruchfeld, A, Fliser, D, Fouque, D, Frische, S, Gesualdo, L, Gutierrez, E, Goumenos, D, Hoorn, Ewout, Eckardt, KU, Knauss, S, Konig, M, Malyszko, J, Massy, Z, Nitsch, D, Pesce, F, Rychlik, I, Soler, MJ, Spasovski, G, Stevens, KI, Trepiccione, F, Wanner, C, Wiecek, A, Zoccali, C, Unwin, R, and Capasso, G

Published
2020

13. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement

Author

Locatelli, Francesco, Bárány, Peter, Covic, Adrian, De Francisco, Angel, Del Vecchio, Lucia, Goldsmith, David, Hörl, Walter, London, Gerard, Vanholder, Raymond, Van Biesen, Wim, Abramovicz, D., Cannata-Andia, J., Cochat, P., Eckardt, K. U., Fouque, D., Heimburger, O., Jäger, K., Jenkins, S., Lindley, E., MacLeod, A., Marti-Monros, A., Tattersall, J., Wiecek, A., and Wanner, C.

Published
2013
Full Text
View/download PDF

18. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine

Author

Capasso, A., Benigni, A., Capitanio, U., Danesh, F. R., Di Marzo, V., Gesualdo, L., Grandaliano, Giuseppe, Jaimes, E. A., Malyszko, J., Perazella, M. A., Qian, Q., Ronco, P., Rosner, M. H., Trepiccione, F., Viggiano, D., Zoccali, C., Capasso, G., Akitaka, A., Alahoti, A., Alexander, T. R., Altucci, L., Amer, H., Barone, V., Biancone, L., Bonventre, J. V., Camussi, G., Ciardiello, F., Caraglia, M., Carteni, G., Cervantes, A., Citterio, Franco, Cosmai, L., Daniele, B., D'Errico, A., De Vita, F., Ereditato, A., Falco, G., Fouque, D., Franco, R., Gallieni, M., Gambaro, G., Kuo, C., Launay-Vacher, V., Maiello, E., Mallamaci, F., Malysxko, J., Marino, G., Martinelli, E., Matarese, G., Matsubara, T., Messa, P., Messina, C., Mirone, V., Morgillo, F., Costa, A. N., Orditura, M., Pani, A., Perna, A., Pisano, C., Pitts, T., Porta, C., Procopio, G., Remuzzi, G., Russo, D., Siu, L. L., Stadler, W., Troiani, T., Weisz, A., Wiecek, A., Xiaoqiang, D., Zecchino, O., Grandaliano G. (ORCID:0000-0003-1213-2177), Citterio F. (ORCID:0000-0003-0489-6337), Capasso, A., Benigni, A., Capitanio, U., Danesh, F. R., Di Marzo, V., Gesualdo, L., Grandaliano, Giuseppe, Jaimes, E. A., Malyszko, J., Perazella, M. A., Qian, Q., Ronco, P., Rosner, M. H., Trepiccione, F., Viggiano, D., Zoccali, C., Capasso, G., Akitaka, A., Alahoti, A., Alexander, T. R., Altucci, L., Amer, H., Barone, V., Biancone, L., Bonventre, J. V., Camussi, G., Ciardiello, F., Caraglia, M., Carteni, G., Cervantes, A., Citterio, Franco, Cosmai, L., Daniele, B., D'Errico, A., De Vita, F., Ereditato, A., Falco, G., Fouque, D., Franco, R., Gallieni, M., Gambaro, G., Kuo, C., Launay-Vacher, V., Maiello, E., Mallamaci, F., Malysxko, J., Marino, G., Martinelli, E., Matarese, G., Matsubara, T., Messa, P., Messina, C., Mirone, V., Morgillo, F., Costa, A. N., Orditura, M., Pani, A., Perna, A., Pisano, C., Pitts, T., Porta, C., Procopio, G., Remuzzi, G., Russo, D., Siu, L. L., Stadler, W., Troiani, T., Weisz, A., Wiecek, A., Xiaoqiang, D., Zecchino, O., Grandaliano G. (ORCID:0000-0003-1213-2177), and Citterio F. (ORCID:0000-0003-0489-6337)

Abstract

Onco-nephrology is an emerging field in medicine. Patients with cancer may suffer from kidney diseases because of the cancer itself and cancer-related therapy. It is critical for nephrologists to be knowledgeable of cancer biology and therapy in order to be fully integrated in the multidisciplinary team and optimally manage patients with cancer and kidney diseases. In a recent international meeting, the key issues in this challenging clinical interface were addressed, including many unresolved basic science questions, such as the high tumor incidence in kidney transplant recipients. To this end, 70 highly qualified faculty members were gathered from all over the world to discuss these issues in 8 plenary sessions, including 5 keynote lectures. In addition, 48 young nephrologists and oncologists were invited to present their original observations that were highlighted in 2 large poster sessions.

Published
2019

20. The systemic nature of CKD

Author

Zoccali, C., Vanholder, R., Massy, Z.A., Ortiz, A., Sarafidis, P., Dekker, F.W., Fliser, D., Fouque, D., Heine, G.H., Jager, K.J., Kanbay, M., Mallamaci, F., Parati, G., Rossignol, P., Wiecek, A., London, G., European Renal Cardiovascular Medi, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Zoccali, C, Vanholder, R, Massy, Z, Ortiz, A, Sarafidis, P, Dekker, F, Fliser, D, Fouque, D, Heine, G, Jager, K, Kanbay, M, Mallamaci, F, Parati, G, Rossignol, P, Wiecek, A, London, G, Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National de la Recherche Agronomique (INRA)

Subjects
Lung Diseases, Nephrology, CHRONIC KIDNEY-DISEASE, Pathology, Systemic disease, SYMPATHETIC-NERVOUS-SYSTEM, SMOOTH-MUSCLE-CELLS, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, Disease, 030204 cardiovascular system & hematology, Bioinformatics, Lung Disease, GLOMERULAR-FILTRATION-RATE, 0302 clinical medicine, OBSTRUCTIVE SLEEP-APNEA, Medicine, Wasting, Nervous System Disease, STAGE RENAL-DISEASE, PULMONARY NEUROENDOCRINE, 3. Good health, FIBROBLAST GROWTH FACTOR-23, Heart Disease, Bone Diseases, medicine.symptom, Human, medicine.medical_specialty, Heart Diseases, Systems biology, Renal function, Metabolic bone disease, 03 medical and health sciences, Metabolic Diseases, LEFT-VENTRICULAR HYPERTROPHY, Internal medicine, Animals, Humans, Renal Insufficiency, Chronic, Inflammation, business.industry, Animal, Immunity, medicine.disease, Metabolic Disease, CELLS, Nervous System Diseases, business, Bone Disease, Energy Metabolism, TRIMETHYLAMINE-N-OXIDE, Kidney disease
Abstract

International audience; The accurate definition and staging of chronic kidney disease (CKD) is one of the major achievements of modern nephrology. Intensive research is now being undertaken to unravel the risk factors and pathophysiologic underpinnings of this disease. In particular, the relationships between the kidney and other organs have been comprehensively investigated in experimental and clinical studies in the last two decades. Owing to technological and analytical limitations, these links have been studied with a reductionist approach focusing on two organs at a time, such as the heart and the kidney or the bone and the kidney. Here, we discuss studies that highlight the complex and systemic nature of CKD. Energy balance, innate immunity and neuroendocrine signalling are highly integrated biological phenomena. The diseased kidney disrupts such integration and generates a high-risk phenotype with a clinical profile encompassing inflammation, protein-energy wasting, altered function of the autonomic and central nervous systems and cardiopulmonary, vascular and bone diseases. A systems biology approach to CKD using omics techniques will hopefully enable in-depth study of the pathophysiology of this systemic disease, and has the potential to unravel critical pathways that can be targeted for CKD prevention and therapy.

Published
2017
Full Text
View/download PDF

21. Association of a Low-Protein Diet With Slower Progression of CKD

Author

Metzger, M., Yuan, W.L., Haymann, J.P., Flamant, M., Houillier, P., Thervet, E., Boffa, J.J., Vrtovsnik, F., Froissart, M., Bankir, L., Fouque, D., Stengel, B., Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Métabolisme et physiologie rénale (CRC - UMR_S 1138), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Descartes - Paris 5 (UPD5), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Service de néphrologie, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), The NephroTest CKD cohort study was supported by the following grants: INSERM GIS-IReSP AO 8113LS TGIR (BS), French Ministry of Health AOM 09114 (MFr), INSERM AO 8022LS (BS), Agence de la Biomédecine R0 8156LL (B.S.), AURA (MFr), and Roche 2009-152-447G (MFr)., Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), CHU Tenon [APHP], Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pillet, Lauriane, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre National de la Recherche Scientifique (CNRS)-Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
glomerular filtration rate, function, end-stage renal disease, vasopressin, [SDV]Life Sciences [q-bio], restriction, urinary urea excretion, dietary protein intake, Urology & Nephrology, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, decline, mortality, rate, [SDV] Life Sciences [q-bio], term-follow-up, nutrition, prevention, Clinical Research, glomerular filtration, mdrd, adherence, chronic kidney-disease, chronic renal-disease
Abstract

Open access article; International audience; Introduction: Reducing protein intake is recommended for slowing chronic kidney disease (CKD) progression, but assessment of its true effectiveness is sparse. Methods: Using the Maroni formula, we assessed dietary protein intake (DPI) from 24-hour urinary urea excretion in 1594 patients (67% men and 33% women) with CKD, 784 of whom also had 7-day food records. Cause-specific hazard ratios (HRs) and 95% confidence intervals for the competing risks of DPI-associated end-stage renal disease (ESRD) or death were estimated in 1412 patients with baseline glomerular filtration rate \textgreater= 15 ml/min per 1.73 m(2), measured by Cr-51-EDTA renal clearance (mGFR). Results: Overall, mean DPI estimated from urea excretion was 1.09 +/- 0.30 g/kg of body weight per day (range = 0.34 - 2.76); 20% of patients had values \textgreater 1.3 g/kg per day, and 1.9% had values \textless 0.6 g/kg per day. Urea excretion and food records produced similar estimates of mean DPI. The lower the mGFR, the lower the mean DPI. Over a median follow-up of 5.6 years, there were 319 ESRD events and 189 pre-ESRD deaths. After adjusting for relevant covariates, each 0.1 g/kg daily higher baseline urea excretion - based DPI or food record - based DPI was associated with an HR for ESRD of 1.05 (95% confidence interval 1.01 - 1.10) or 1.09 (95% confidence interval 1.04 - 1.14), respectively. HRs were stronger in patients with baseline mGFR \textless 30 ml/min per 1.73 m(2). There was no association with mortality. The mean age of the patients was 59 +/- 15 years, and mean body mass index was 26.6 +/- 5.2 kg/m(2). Conclusion: In this prospective observational study, the lower the baseline DPI, the slower the progression toward ESRD. Most importantly, the absence of threshold for the relation between DPI and ESRD risk indicates that there is no optimal DPI in the range observed in this cohort.

Published
2018
Full Text
View/download PDF

22. Mediterranean diet as the diet of choice for patients with chronic kidney disease

Author

Chauveau P, Aparicio M, Bellizzi V, Campbell K, Hong X, Johansson L, Kolko A, MOLINA, P, Sezer S, Wanner C, Ter Wee PM, Teta D, Fouque D, Carrero JJ, and European Renal Nutrition (ERN) Working Group of the European Renal Association-E

Abstract

Traditional dietary management of chronic kidney disease (CKD) focuses on the quantity within the diet of energy and protein, and the restriction of single micronutrients, with little mention of dietary quality. Dietary patterns that are more plant-based, lower in meat (including processed meat), sodium and refined sugar, and have a higher content of grains and fibres are now included in multiple clinical guidelines for chronic disease prevention. The Mediterranean diet (MD) has been associated with reduced cardiovascular disease incidence in both observational and interventional studies. A wealth of evidence links MD with other beneficial effects on chronic diseases such as diabetes, obesity or cognitive health. This review examines each constituent of the classical MD and evaluates their suitability for the management of patients with CKD. We also evaluate the potential hyperkalaemia risk of increasing fruit and vegetable intake. Overall, a decrease in net endogenous acid production and increase in fibre may lead to a better control of metabolic acidosis. This, together with other putative favourable effects of MD on endothelial function, inflammation, lipid profile and blood pressure, provide mechanistic pathways to explain the observed reduced renal function decline and improved survival in CKD patients adhering to an MD.

Published
2018

23. The effect of high-volume online haemodiafiltration on nutritional status and body composition: the ProtEin Stores prEservaTion (PESET) study

Author

Molina P, Vizcaíno B, Molina MD, Beltrán S, González-Moya M, Mora A, Castro-Alonso C, Kanter J, Ávila AI, Górriz JL, Estañ N, Pallardó LM, Fouque D, and Carrero JJ

Subjects
haemodialysis, body composition, nutrition, protein-energy wasting, haemodiafiltration
Abstract

Background. Compared with conventional haemodialysis (HD), online haemodiafiltration (OL-HDF) achieves a more efficient removal of uraemic toxins and reduces inflammation, which could favourably affect nutritional status. We evaluate the effect of OL-HDF on body composition and nutritional status in prevalent high-flux HD (HF-HD) patients. Methods. In all, 33 adults with chronic kidney disease (CKD) Stage 5 undergoing maintenance HF-HD were assigned to post-dilution OL-HDF (n = 17) or to remain on HF-HD (n = 16, control group) for 12 months. The primary outcome was the change in lean tissue mass (LTM), intracellular water (ICW) and body cellmass (BCM) assessed by multifrequency bioimpedance spectroscopy (BIS) at baseline and 4, 8 and 12 months. The rate of change in these parameters was estimated with linearmixed- effectsmodels. Results. Compared with OL-HDF, patients assigned to HF-HD experienced a gradual reduction in LTM, ICWand BCM. These differences reached statistical significance at Month 12, with a relative difference of 7.31 kg [95% confidence interval (CI) 2.50-12.11; P = 0.003], 2.32 L (95% CI 0.63-4.01; P = 0.008) and 5.20 kg (95% CI 1.74-8.66; P = 0.004) for LTM, ICW and BCM, respectively. The normalized protein appearance increased in the OL-HDF group compared with the HF-HD group [0.26 g/kg/day (95% CI 0.05-0.47); P = 0.002], with a relative reduction in high-sensitive C-reactive protein [-13.31 mg/dL (95% CI -24.63 to -1.98); P = 0.02] atMonth 12. Conclusions. OL-HDF for 1 year compared with HF-HD preserved muscle mass, increased protein intake and reduced the inflammatory state related to uraemia and dialysis, supporting the hypothesis that high convection volume can benefit nutritional status and prevent protein-energy wasting in HD patients.

Published
2018

24. Acute renal and splenic infarctions: a review

Author

Weber, E, primary, Grangeon, F, additional, Reynaud, Q, additional, Hot, A, additional, Sève, P, additional, Jardel, S, additional, Tazarourte, K, additional, Fouque, D, additional, Juillard, L, additional, Salles, G, additional, Grange, C, additional, Durieu, I, additional, Rousset, P, additional, and Lega, J C, additional

Published
2019
Full Text
View/download PDF

25. Acute renal and splenic infarctions: a review.

Author

Weber, E, Grangeon, F, Reynaud, Q, Hot, A, Sève, P, Jardel, S, Tazarourte, K, Fouque, D, Juillard, L, Salles, G, Grange, C, Durieu, I, Rousset, P, and Lega, J C

Subjects
INFARCTION, VENOUS thrombosis, ARTERIAL diseases, ABDOMINAL pain, ARTERIAL injuries
Abstract

Background Renal and splenic infarctions are close entities, with few data concerning their clinical, biological and radiological features. Aim The aim of this study was to compare the clinical presentations, etiologies and outcomes of acute renal infarctions (RI) and splenic infarctions (SI). Design A retrospective multicentric cohort study included patients of the 6 university hospitals in Lyon with RI, SI, or associated RI-SI infarctions was conducted. Methods All consecutive cases diagnosed by CT imaging, between January 2013 and October 2016, were included. The exclusion criteria were causes of infarction that did not require additional investigations. Results A total of 161 patients were selected for analysis: 34 patients with RI, 104 patients with SI and 23 patients with both RI-SI. Mean ± SD age of patients was 63.2 ± 16.6 years; 59.6% were male. Only 5/161 (3.1%) were healthy prior to the event. The main symptoms were diffuse abdominal pain (26.4%), followed by nausea/vomiting (18.3%) and fever (16.4%).The causes of RI or SI varied significantly within the three groups. Hypercoagulable state was associated with SI, and embolic disease and arterial injury were associated with RI. Extensive (i.e.>2/3 of organ volume) (OR 6.22, 95%CI 2.0119.22) and bilateral infarctions (OR 15.05, 95%CI 1.79–126.78) were significantly associated with hemodynamic shocks. The survival at 1 month follow-up did not significantly differ between the three groups. Conclusion Acute RI and SI are heterogenous entities in regards to their clinical presentation, etiology, associated venous or arterial thrombosis, but prognoses were not different at short term follow-up. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

29. The systemic nature of CKD

Author

Zoccali, C, Vanholder, R, Massy, Z, Ortiz, A, Sarafidis, P, Dekker, F, Fliser, D, Fouque, D, Heine, G, Jager, K, Kanbay, M, Mallamaci, F, Parati, G, Rossignol, P, Wiecek, A, London, G, PARATI, GIANFRANCO, London, G., Zoccali, C, Vanholder, R, Massy, Z, Ortiz, A, Sarafidis, P, Dekker, F, Fliser, D, Fouque, D, Heine, G, Jager, K, Kanbay, M, Mallamaci, F, Parati, G, Rossignol, P, Wiecek, A, London, G, PARATI, GIANFRANCO, and London, G.

Abstract

The accurate definition and staging of chronic kidney disease (CKD) is one of the major achievements of modern nephrology. Intensive research is now being undertaken to unravel the risk factors and pathophysiologic underpinnings of this disease. In particular, the relationships between the kidney and other organs have been comprehensively investigated in experimental and clinical studies in the last two decades. Owing to technological and analytical limitations, these links have been studied with a reductionist approach focusing on two organs at a time, such as the heart and the kidney or the bone and the kidney. Here, we discuss studies that highlight the complex and systemic nature of CKD. Energy balance, innate immunity and neuroendocrine signalling are highly integrated biological phenomena. The diseased kidney disrupts such integration and generates a high-risk phenotype with a clinical profile encompassing inflammation, protein-energy wasting, altered function of the autonomic and central nervous systems and cardiopulmonary, vascular and bone diseases. A systems biology approach to CKD using omics techniques will hopefully enable in-depth study of the pathophysiology of this systemic disease, and has the potential to unravel critical pathways that can be targeted for CKD prevention and therapy.

Published
2017

30. [Accepted Manuscript] Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m2)

Author

Farrington, K., Covic, A., Aucella, F., Clyne, N., de Vos, L., Findlay, A., Fouque, D., Grodzicki, T., Iyasere, O., Jager, K.J., Joosten, H., Macias, J.F., Mooney, A., Nitsch, D., Stryckers, M., Taal, M., Tattersall, J., Van Asselt, D., Van den Noortgate, N., Nistor, I., Van Biesen, W., ERBP guideline development group, ., COLLABORATORS, De Vos, L., Núñez, J.F., van Asselt, D., and Van Den Noortgate, N.

Published
2016

31. Authors' Reply: The Potential Outcome-Modification Influences Introduced by ESKD Life Plan on eGFR Slopes

Author

Tabcheh, Abdel-Hay, Boucquemont, Julie, Pecoits-Filho, Roberto, Alencar De Pinho, Natalia, Stengel, Bénédicte, Metzger, Marie, Speyer, Elodie, Lange, Céline, Hannedouche, T., Moulin, B., Klein, A., Combe, C., Bourdenx, J.P., Keller, A., Delclaux, C., Vendrely, B., Deroure, B., Lacraz, A., Lobbedez, T., Landru, I., Massy, Z., Lang, P., Belenfant, X., Thervet, E., Urena, P., Delahousse, M., Vela, C., Essig, M., Clément, D., Sekhri, H., Smati, M., Jamali, M., Hacq, B., Panescu, V., Bellou, M., Frimat, Luc, Kamar, N., Noël, C., Glowacki, F., Maisonneuve, N., Azar, R., Hoffmann, M., Hourmant, M., Testa, A., Besnier, D., Choukroun, G., Lambrey, G., Burtey, S., Lebrun, G., Magnant, E., Laville, M., Fouque, D., Juillard, L., Chazot, C., Zaoui, P., and Kuentz, F.

Published
2024
Full Text
View/download PDF

32. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry

Author

Vogelzang, J.L., Stralen, K.J. van, Noordzij, M., Diez, J.A., Carrero, J.J., Couchoud, C., Dekker, F.W., Finne, P., Fouque, D., Heaf, J.G., Hoitsma, A.J., Leivestad, T., Meester, J. de, Metcalfe, W., Palsson, R., Postorino, M., Ravani, P., Vanholder, R., Wallner, M., Wanner, C., Groothoff, J.W., Jager, K.J., Vogelzang, J.L., Stralen, K.J. van, Noordzij, M., Diez, J.A., Carrero, J.J., Couchoud, C., Dekker, F.W., Finne, P., Fouque, D., Heaf, J.G., Hoitsma, A.J., Leivestad, T., Meester, J. de, Metcalfe, W., Palsson, R., Postorino, M., Ravani, P., Vanholder, R., Wallner, M., Wanner, C., Groothoff, J.W., and Jager, K.J.

Abstract

Item does not contain fulltext, BACKGROUND: Infections and malignancies are the most common non-cardiovascular causes of death in patients on chronic renal replacement therapy (RRT). Here, we aimed to quantify the mortality risk attributed to infections and malignancies in dialysis patients and kidney transplant recipients when compared with the general population by age group and sex. METHODS: We followed 168 156 patients included in the ERA-EDTA registry who started RRT in 1993-2007 until 1 January 2012. Age- and cause-specific mortality rates per 1000 person-years (py) and mortality rate ratios (MRRs) compared with the European general population (WHO) were calculated. To identify risk factors, we used Cox regression. RESULTS: Infection-related mortality was increased 82-fold in dialysis patients and 32-fold in transplant recipients compared with the general population. Female sex, diabetes, cancer and multisystem disease were associated with an increased risk of infection-related mortality. The sex difference was most pronounced for dialysis patients aged 0-39 years, with women having a 32% (adjusted HR 1.32 95% CI 1.09-1.60) higher risk of infection-related mortality than men. Mortality from malignancies was 2.9 times higher in dialysis patients and 1.7 times higher in transplant recipients than in the general population. Cancer and multisystem disease as primary causes of end-stage renal disease were associated with higher mortality from malignancies. CONCLUSION: Infection-related mortality is highly increased in dialysis and kidney transplant patients, while the risk of malignancy-related death is moderately increased. Young women on dialysis may deserve special attention because of their high excess risk of infection-related mortality. Further research into the mechanisms, prevention and optimal treatment of infections in this vulnerable population is required.

Published
2015

34. Expert Working Group Report on nutrition in adult patients with renal insufficiency

Author

TOIGO G, APARICIO M, ATTMAN PO, CANO N, ENGEL B, FOUQUE D, HEIDLAND A, TEPLAN V, WANNER C., CIANCIARUSO, BRUNO, Toigo, Gabriele, M., Aparicio, P. O., Attman, N., Cano, B., Cianciaruso, B., Engel, D., Fouque, A., Heidland, V., Teplan, C., Wanner, Toigo, G, Aparicio, M, Attman, Po, Cano, N, Cianciaruso, Bruno, Engel, B, Fouque, D, Heidland, A, Teplan, V, and Wanner, C.

Published
2000

35. FP409SEVELAMER CARBONATE REDUCES PHOSPHATURIA BUT HAS NO EFFECT ON SERUM C-TERMINAL FIBROBLAST GROWTH FACTOR 23 LEVELS IN STAGE 3B/4 CKD PATIENTS : THE RESULTS OF A FRENCH, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROL, RANDOMIZED CLINICAL TRIAL

Author

Liabeuf, S., primary, Ryckelink, J.p., additional, El Esper, N., additional, Urena, P., additional, Combe, C., additional, Dussol, B., additional, Fouque, D., additional, Vanhille, P., additional, Frimat, L., additional, Thervet, E., additional, Prié, D., additional, and Choukroun, G., additional

Published
2015
Full Text
View/download PDF

36. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry

Author

Vogelzang, J. L., primary, van Stralen, K. J., additional, Noordzij, M., additional, Diez, J. A., additional, Carrero, J. J., additional, Couchoud, C., additional, Dekker, F. W., additional, Finne, P., additional, Fouque, D., additional, Heaf, J. G., additional, Hoitsma, A., additional, Leivestad, T., additional, de Meester, J., additional, Metcalfe, W., additional, Palsson, R., additional, Postorino, M., additional, Ravani, P., additional, Vanholder, R., additional, Wallner, M., additional, Wanner, C., additional, Groothoff, J. W., additional, and Jager, K. J., additional

Published
2015
Full Text
View/download PDF

37. A cold Neptune-mass planet ogle-2007-blg-368lb: cold Neptunes are common

Author

Sumi D.P. Bennett I.A. Bond A. Udalski V. Batista M. Dominik P. Fouque D. Kubas A. Gould B. Macintosh K. Cook S. Dong L. Skuljan A. Cassan F. Abe C.S. Botzler A. Fukui K. Furusawa J.B. Hearnshaw Y. Itow K. Kamiya P.M. Kilmartin A. Korpela W. Lin C.H. Ling, T., Univers, Transport, Interfaces, Nanostructures, Atmosphère et environnement, Molécules (UMR 6213) (UTINAM), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

38. EBPG guideline on haemodynamic instability

Author

Kooman J., Basci A., Pizzarelli F., Canaud B., Haage P., Fouque D., Konner K., Martin-Malo A., Pedrini L., Tattersall J., Tordoir J., Vennegoor M., Wanner C., Wee P., Vanholder R., and Ege Üniversitesi

Subjects
ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, ComputingMethodologies_PATTERNRECOGNITION, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, InformationSystems_MISCELLANEOUS
Abstract

PubMed ID: 17507425, [No abstract available]

Published
2007

39. EBPG guideline on dialysis strategies

Author

Tattersall J., Martin-Malo A., Pedrini L., Basci A., Canaud B., Fouque D., Haage P., Konner K., Kooman J., Pizzarelli F., Tordoir J., Vennegoor M., Wanner C., Wee P., Vanholder R., and Ege Üniversitesi

Subjects
ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, ComputingMethodologies_PATTERNRECOGNITION, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, InformationSystems_MISCELLANEOUS
Abstract

PubMed ID: 17507427, [No abstract available]

Published
2007

41. DIALYSIS GENERAL

Author

Panaye, M., primary, Kolko-Labadens, A., additional, Lasseur, C., additional, Paillasseur, J. L., additional, Guillodo, M. P., additional, Levannier, M., additional, Teta, D., additional, Fouque, D., additional, Van Der Veer, S. N., additional, Van De Luijtgaarden, M. W., additional, Brown, E. A., additional, Jager, K. J., additional, Van Biesen, W., additional, Canaud, B., additional, Bayh, I., additional, Marcelli, D., additional, Ponce, P., additional, Merello, J. I., additional, Gurevich, K., additional, Ladanyi, E., additional, Ok, E., additional, Grassmann, A., additional, Scatizzi, L., additional, Gatti, E., additional, Lofaro, D., additional, Vogelzang, J. L., additional, Van Stralen, K. J., additional, Groothoff, J. W., additional, Huber, L., additional, Saith, S., additional, Kheda, M., additional, Baer, S., additional, Nahman, N., additional, Colombo, R., additional, and Kintziger, K., additional

Published
2014
Full Text
View/download PDF

42. UREMIC TOXICITY

Author

Hage, V., primary, Pelletier, S., additional, Dubourg, L., additional, Drai, J., additional, Cuerq, C., additional, Lemoine, S., additional, Hadj-Aissa, A., additional, Laville, M., additional, Fouque, D., additional, Chinnappa, S., additional, Tan, L. B., additional, Mooney, A., additional, El Nahas, A. M., additional, Glorieux, G., additional, Vanholder, R., additional, White, E., additional, Jankowski, J., additional, Janke, D., additional, Ruth, M., additional, Lemke, H.-D., additional, Jankowski, V., additional, Troeger, T., additional, Wessely, M., additional, Bidlingmaier, M., additional, Schonermarck, U., additional, Hadjamu, N., additional, Rau, S., additional, Fischereder, M., additional, Kim, Y., additional, Hong, Y. A., additional, Kim,, M. Y., additional, Lim, J. H., additional, Chang, Y. S., additional, and Park, C. W., additional

Published
2014
Full Text
View/download PDF

44. PERITONEAL DIALYSIS 2

Author

Vlahu, C. A., primary, De Graaff, M., additional, Struijk, D. G., additional, Krediet, R. T., additional, Shin, H.-S., additional, Ryu, E.-S., additional, Choi, H.-S., additional, Ryu, D.-R., additional, Choi, K.-B., additional, Kang, D.-H., additional, Sanchez-Alvarez, E., additional, Rodriguez-Suarez, C., additional, Galvan-.Hernandez, J. A., additional, Kim, Y. L., additional, Kee, Y. K., additional, Lee, M. J., additional, Oh, H. J., additional, Park, J. T., additional, Han, S. H., additional, Yoo, T.-H., additional, Kang, S.-W., additional, Zhu, F., additional, Abbas, S. R., additional, Bologa, R., additional, Lanto, B., additional, Kotanko, P., additional, Parikova, A., additional, Smit, W., additional, Rroji ( Molla), M., additional, Seferi, S., additional, Cafka, M., additional, Thereska, N., additional, Huang, C.-C., additional, Wang, I.-K., additional, Shiao, Y.-T., additional, Teixeira, L., additional, Sousa, I., additional, Rodrigues, A., additional, Mendonca, D., additional, Ueda, A., additional, Iwase, M., additional, Usui, T., additional, Hirayama, A., additional, Nagai, K., additional, Saito, C., additional, Yamagata, K., additional, La Milia, V., additional, Pontoriero, G., additional, Locatelli, F., additional, Kim, S. M., additional, Kim, T. Y., additional, Lee, J. E., additional, Teta, D., additional, Guillodo, M.-P., additional, Kolko-Labadens, A., additional, Lasseur, C., additional, Levannier, M., additional, Panaye, M., additional, Fouque, D., additional, HAMADA, C., additional, Hara, K., additional, Kang, S. H., additional, Cho, K. H., additional, Park, J. W., additional, Yoon, K. W., additional, Do, J. Y., additional, Dogan, I., additional, Biro Dr, B., additional, Zakar Dr, G., additional, Foldine, Z., additional, Staudt, S., additional, Martins, A. R., additional, Vizinho, R., additional, Branco, P. Q., additional, Gaspar, M. A., additional, Barata, J. D., additional, Sikorska, D., additional, Klysz, P., additional, Posnik, B., additional, Baum, E., additional, Hoppe, K., additional, Schwermer, K., additional, Wanic-Kossowska, M., additional, Frankiewicz, D., additional, Pawlaczyk, K., additional, Lindholm, B., additional, Oko, A., additional, Busuioc, M., additional, Trolliet, P., additional, Guerraoui, A., additional, Caillette-Beaudoin, A., additional, Hallonet, P., additional, Yang, J.-O., additional, Gursu, M., additional, Topcuoglu, D., additional, Koc, L. K., additional, Yucel, L., additional, Sumnu, A., additional, Cebeci, E., additional, Doner, B., additional, Ozkan, O., additional, Behlul, A., additional, Koc, L., additional, Ozturk, S., additional, Kazancioglu, R., additional, Casas Parra, A. I. I., additional, Gonzalez, M. T. T., additional, Sandoval, D. A., additional, Carlota, G. C., additional, Grinyo, J. M. M., additional, Tseng, C.-H., additional, Chao, C.-T., additional, Yen, C.-J., additional, Chiang, C.-K., additional, Hung, K.-Y., additional, Huang, J.-W., additional, Al Wakeel, J. S., additional, Al Ghonaim, M., additional, Al Suwaida, A., additional, Al Harbi, A., additional, Makoshi, Z., additional, Abdullah, S., additional, Matsushita, Y., additional, Basic-Jukic, N., additional, Coen-Herak, D., additional, Martinovic, Z., additional, Radi -Antoli , M., additional, Kes, P., additional, Wu, T.-J., additional, Chen, J.-S., additional, Lin, S.-H., additional, Shiang, J.-C., additional, Wu, C.-C., additional, Munteanu, D., additional, Gemene, M., additional, Mircescu, G., additional, Opatrna, S., additional, Popperlova, A., additional, Tesar, V., additional, Rychlik, I., additional, Viklicky, O., additional, Jin, K., additional, Park, B.-S., additional, Jeong, H. J., additional, Kim, Y.-W., additional, Hogas, S., additional, Voroneanu, L., additional, Onofriescu, M., additional, Nistor, I., additional, Apetrii, M., additional, Siriopol, D., additional, Cujba, M., additional, Hogas, M., additional, and Covic, A., additional

Published
2014
Full Text
View/download PDF

45. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Author

Legendre, C.M., Licht, C., Muus, P., Greenbaum, L.A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D.J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R.R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nurnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N.S., Trivelli, A., Zimmerhackl, L.B., Goodship, T., Loirat, C., Legendre, C.M., Licht, C., Muus, P., Greenbaum, L.A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D.J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R.R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nurnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N.S., Trivelli, A., Zimmerhackl, L.B., Goodship, T., and Loirat, C.

Abstract

Item does not contain fulltext, BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease. METHODS: We conducted two prospective phase 2 trials in which patients with atypical hemolytic-uremic syndrome who were 12 years of age or older received eculizumab for 26 weeks and during long-term extension phases. Patients with low platelet counts and renal damage (in trial 1) and those with renal damage but no decrease in the platelet count of more than 25% for at least 8 weeks during plasma exchange or infusion (in trial 2) were recruited. The primary end points included a change in the platelet count (in trial 1) and thrombotic microangiopathy event-free status (no decrease in the platelet count of >25%, no plasma exchange or infusion, and no initiation of dialysis) (in trial 2). RESULTS: A total of 37 patients (17 in trial 1 and 20 in trial 2) received eculizumab for a median of 64 and 62 weeks, respectively. Eculizumab resulted in increases in the platelet count; in trial 1, the mean increase in the count from baseline to week 26 was 73x10(9) per liter (P<0.001). In trial 2, 80% of the patients had thrombotic microangiopathy event-free status. Eculizumab was associated with significant improvement in all secondary end points, with continuous, time-dependent increases in the estimated glomerular filtration rate (GFR). In trial 1, dialysis was discontinued in 4 of 5 patients. Earlier intervention with eculizumab was associated with significantly greater improvement in the estimated GFR. Eculizumab was also associated with improvement in health-related quality of life. No cumulative toxicity of therapy or serious infection-related adverse events, including meningococcal infections, were observed through the extension period. CONCLUSIONS: Eculizumab inhibited complement-mediated

Published
2013

46. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome

Author

Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R. R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, Diana, Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nuernberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N. S., Trivelli, A., Zimmerhackl, L. B., Goodship, T., Loirat, C., Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R. R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, Diana, Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nuernberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N. S., Trivelli, A., Zimmerhackl, L. B., Goodship, T., and Loirat, C.

Abstract

Background Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease. Methods We conducted two prospective phase 2 trials in which patients with atypical hemolytic-uremic syndrome who were 12 years of age or older received eculizumab for 26 weeks and during long-term extension phases. Patients with low platelet counts and renal damage (in trial 1) and those with renal damage but no decrease in the platelet count of more than 25% for at least 8 weeks during plasma exchange or infusion (in trial 2) were recruited. The primary end points included a change in the platelet count (in trial 1) and thrombotic microangiopathy event-free status (no decrease in the platelet count of >25%, no plasma exchange or infusion, and no initiation of dialysis) (in trial 2). Results A total of 37 patients (17 in trial 1 and 20 in trial 2) received eculizumab for a median of 64 and 62 weeks, respectively. Eculizumab resulted in increases in the platelet count; in trial 1, the mean increase in the count from baseline to week 26 was 73x10(9) per liter (P<0.001). In trial 2, 80% of the patients had thrombotic microangiopathy event-free status. Eculizumab was associated with significant improvement in all secondary end points, with continuous, time-dependent increases in the estimated glomerular filtration rate (GFR). In trial 1, dialysis was discontinued in 4 of 5 patients. Earlier intervention with eculizumab was associated with significantly greater improvement in the estimated GFR. Eculizumab was also associated with improvement in health-related quality of life. No cumulative toxicity of therapy or serious infection-related adverse events, including meningococcal infections, were observed through the extension period. Conclusions Eculizumab inhibited complement-mediated thr

Published
2013

47. 'Real-World' use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study

Author

Vervloet, M, Bencova, V, Malberti, F, Ashman, N, Os, I, Saha, H, Ureña, P, Zitt, E, Rix, M, Ryba, M, Fouque, D, Dehmel, B, Petavy, F, Jacobson, Stephen, Vervloet, M, Bencova, V, Malberti, F, Ashman, N, Os, I, Saha, H, Ureña, P, Zitt, E, Rix, M, Ryba, M, Fouque, D, Dehmel, B, Petavy, F, and Jacobson, Stephen

Abstract

The pan-European ECHO observational study evaluated cinacalcet in adult dialysis patients with secondary hyperparathyroidism (SHPT) in "real-world" clinical practice. A sub-analysis compared data for 7 European countries/country clusters: Austria, CEE (Czech Republic and Slovakia), France, Italy, Netherlands, Nordics (Denmark, Finland, Norway, and Sweden), and the UK/Ireland.

Published
2010

48. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study

Author

Urena, P., Jacobson, S.H., Zitt, E., Vervloet, M., Malberti, F., Ashman, N., Leavey, S., Rix, M., Os, I., Saha, H., Ryba, M., Bencova, V., Banos, A., Zani, V., Fouque, D., Urena, P., Jacobson, S.H., Zitt, E., Vervloet, M., Malberti, F., Ashman, N., Leavey, S., Rix, M., Os, I., Saha, H., Ryba, M., Bencova, V., Banos, A., Zani, V., and Fouque, D.

Abstract

BACKGROUND: The use and effectiveness of cinacalcet in 'real-world' clinical practice was investigated in a pan-European observational study in dialysis patients with secondary hyperparathyroidism (SHPT) of varying severity. METHODS: Adult patients with chronic kidney disease on dialysis who had initiated cinacalcet treatment were enrolled. Data were collected 6 months before initiating cinacalcet, at baseline (initiation of cinacalcet) and up to 12 months after cinacalcet initiation. RESULTS: A total of 1865 patients [mean (SD) age 58 (15) years] were enrolled from 187 sites in 12 countries. Most patients had a dialysis vintage of > or =1 year (1-5 years, n = 833; >5 years, n = 748 versus <1 year, n = 265). The patients generally had severely uncontrolled intact parathyroid hormone (iPTH) serum levels (median 721 pg/ml) and elevated phosphorus (median 5.9 mg/dl) and calcium (median 9.6 mg/dl) at baseline, despite being prescribed conventional therapies. The proportions of patients achieving the recommended [NKF-K/DOQI(TM) (KDOQI(TM))] targets increased from baseline [4%, 39%, 40% and 46% for iPTH, phosphorus, calcium and calcium-phosphorus product (Ca x P), respectively] to Month 12 (28%, 48%, 51% and 68%, respectively). At Month 12, 18% of patients had achieved the combined target for iPTH + Ca x P compared with 2% at baseline. Most patients (65%) received <60 mg/day cinacalcet at Month 12. Vitamin D sterol use remained fairly stable throughout the study. There was a 13% decrease in prescribed sevelamer; use of calcium-based phosphate binders increased by 5.6%. There was no unexpected safety or tolerability concerns. CONCLUSION: This analysis of current European clinical practice shows that-consistent with findings from randomized controlled trials and retrospective observational studies-cinacalcet improves attainment of KDOQI bone metabolism targets in dialysis patients with various stages of SHPT Udgivelsesdato: 2009/9

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results